OncoSil Medical Limited (OSL, NeuroDiscovery Ltd) is an Australia-based and ASX-listed medical device company focused on localised treatments for patients with pancreatic and liver cancer.
OncoSil's lead product, OncoSil, is a first in class medical device with targeted radioactive isotope (Phosphorous-32) implanted directly into a patient's pancreatic tumors via an endoscopic ultrasound. This treatment, known as brachytherapy, is intended to deliver more concentrated and localized radiation.